Almirall plans new trials for COPD drug after Phase III disappointment
This article was originally published in Scrip
Almirallis to continue the development of its inhaled anticholinergic, aclidinium bromide for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD), in partnership with Forest Laboratories, despite disappointing Phase III results from the ACCLAIM/COPD 1 & 2 studies.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.